Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
Price : $35 *
At a glance
- Drugs Pimasertib (Primary) ; Voxtalisib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors EMD Serono; Merck KGaA
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2018 This trial is completed in Spain according to the European Clinical Trials Database record.
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.